Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986361 · ClinicalTrials.gov registry record · Phase 3
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
A Phase 3 study of Sore-throat and Acute Pharyngitis, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT01986361 is a Phase 3 study of Sore-throat and Acute Pharyngitis that has completed, run by Reckitt Benckiser. The registered enrollment target is 122 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01986361, a Phase 3 study of Sore-throat and Acute Pharyngitis, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).
Conditions Studied
Interventions
- DRUG placebo
- DRUG flurbiprofen
Study Locations (1)
Connecticut
- University of Connecticut - Student Health Services - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986361
The ClinicalTrials.gov registry entry for NCT01986361 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sore-throat appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01986361 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01986361 about?
NCT01986361 is a clinical study titled "Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method". The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).
What is the current status of trial NCT01986361?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2013-09. Estimated completion is 2014-04.
What conditions does trial NCT01986361 study?
This clinical trial studies the following conditions: Sore-throat, Acute Pharyngitis.
What interventions are being tested in trial NCT01986361?
The interventions under investigation include: placebo (DRUG), flurbiprofen (DRUG).
Who is sponsoring clinical trial NCT01986361?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986361 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sore-throat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.